NEO 6860

Drug Profile

NEO 6860

Alternative Names: NEO6860; TRPV1 antagonist - NEOMED; Vanilloid receptor 1 ion channel antagonist - NEOMED

Latest Information Update: 21 Mar 2017

Price : $50

At a glance

  • Originator AstraZeneca Canada
  • Developer NEOMED
  • Class Analgesics; Antirheumatics; Benzimidazoles; Small molecules
  • Mechanism of Action TRPV1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Musculoskeletal pain; Neuropathic pain; Visceral pain

Highest Development Phases

  • Phase II Musculoskeletal pain
  • No development reported Neuropathic pain; Visceral pain

Most Recent Events

  • 24 Nov 2016 Neomed Institute completes a phase II trial for Musculoskeletal pain (associated with osteoarthritis of the knee) in Canada (PO) (NCT02712957)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Neuropathic-pain in Canada (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Visceral-pain in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top